Oragenics (NYSE:MKT - OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced selection of a second generation...

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE MKT:OGEN) (the "Company") today announced that NYSE Regulation has accepted the Company's plan to regain compliance with the NYSE MKT exchange's...

Oragenics, Inc. (NYSE MKT: OGEN), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced it has entered into a definitive...

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT - OGEN) has announced today that it met representatives of the Food and Drug Administration ("FDA") in a Pre-IND meeting concerning its lead lantibiotic...

Oragenics, Inc. (NYSE MKT:OGEN) announced today the successful completion of an independent study evaluating the effects of a chewable tablet containing ProBiora3®, in early childhood development of dental caries in...

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE MKT: OGEN) has announced today that, based on proxies submitted to the independent Inspector of Election for its 2015 Annual Meeting of Shareholders, results...

Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and Oragenics (NYSE MKT:OGEN), today announced a new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM)...